Results 161 to 170 of about 6,019 (285)

Automatic Lesion Morphometrics Reliably Predict Sensorimotor Recovery After Spinal Cord Injury: A Longitudinal, Multicenter Neuroimaging Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate automatic magnetic resonance imaging (MRI)‐derived lesion morphometrics against manual measurements and their prognostic value for characterizing distinct acute to chronic neurological recovery trajectories after spinal cord injury (SCI). Methods We studied a retrospective, multicenter cohort of cervical and thoracolumbar
Dario Pfyffer   +28 more
wiley   +1 more source

Cerebrospinal Fluid GAD65‐Antibody Levels Accurately Identify Relevant Neurological Diseases

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Retrospective cohort study to investigate which factors most reliably distinguish incidental GAD65‐antibodies (iGAD65) from true GAD65‐antibody neurological disease (tGAD65). 167 adults with positive serum and CSF GAD65‐antibodies (> 0.02 nmol/L by radioimmunoassay) were classified as tGAD65 or iGAD65, with diagnostic performance of ...
Max Charles Herman   +9 more
wiley   +1 more source

Health Care Use Among Patients Presenting to Emergency Department for Gout Flares in Ontario, Canada: A Population‐Based Health Systems Analysis

open access: yesArthritis Care &Research, EarlyView.
Objective We characterized emergency department (ED) gout visits and identified patient characteristics and health services patterns contributing to ED presentations. Methods We conducted a population‐based study of ED gout visits in Ontario, Canada, between 2014 and 2023.
Timothy S. H. Kwok   +7 more
wiley   +1 more source

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho   +4 more
wiley   +1 more source

Mapping the Social Network Structure and Composition of Black Individuals With Rheumatic and Musculoskeletal Conditions

open access: yesArthritis Care &Research, EarlyView.
Objective Our objective was to describe the social networks of Black individuals with rheumatic and musculoskeletal conditions and understand the clustering of health‐related behaviors to inform future community‐based, peer‐led interventions. Methods We used an adapted Personal Network Survey for Clinical Research (PERSNET) to map the personal social ...
Taussia Boadi   +27 more
wiley   +1 more source

Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes

open access: yesArthritis Care &Research, Accepted Article.
Objective Existing patient‐reported outcome (PRO) measures for systemic sclerosis (SSc) have important limitations, including inadequate coverage of early disease and limited inclusion of diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) subtypes.
George J. Greene   +5 more
wiley   +1 more source

Generative Artificial Intelligence in Clinical Practice: How Should Rheumatologists Evaluate and Monitor Emerging Tools?

open access: yesArthritis Care &Research, EarlyView.
Generative artificial intelligence (AI) is increasingly being used in rheumatology practice, to assist with tasks such as documentation, record summarization, and clinical decision support. Rheumatologists need a practical approach to determining what evidence and oversight each application requires.
Koushan Kouranloo   +2 more
wiley   +1 more source

ANTHELMINTIC EFFECT OF THIABENDAZOLE IN FORMS OF CHEWABLE AND PAMOATE CHEWABLE TABLETS AGAINST HUMAN NEMATODES

open access: yesJapanese Journal of Medical Science and Biology, 1966
ISHIZAKI, TATSUSHI   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy